IL124383A0 - Tissue-specific and target rna-specific ribozymes - Google Patents

Tissue-specific and target rna-specific ribozymes

Info

Publication number
IL124383A0
IL124383A0 IL12438396A IL12438396A IL124383A0 IL 124383 A0 IL124383 A0 IL 124383A0 IL 12438396 A IL12438396 A IL 12438396A IL 12438396 A IL12438396 A IL 12438396A IL 124383 A0 IL124383 A0 IL 124383A0
Authority
IL
Israel
Prior art keywords
ribozymes
specific
target rna
tissue
nucleic acids
Prior art date
Application number
IL12438396A
Other languages
English (en)
Original Assignee
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina filed Critical Univ South Carolina
Publication of IL124383A0 publication Critical patent/IL124383A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12438396A 1995-11-08 1996-11-08 Tissue-specific and target rna-specific ribozymes IL124383A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/554,369 US5824519A (en) 1995-11-08 1995-11-08 Tissue-specific and target RNA-specific ribozymes
PCT/US1996/018088 WO1997017433A1 (fr) 1995-11-08 1996-11-08 Ribozymes specifiques de tissus ou d'arn cible

Publications (1)

Publication Number Publication Date
IL124383A0 true IL124383A0 (en) 1998-12-06

Family

ID=24213065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12438396A IL124383A0 (en) 1995-11-08 1996-11-08 Tissue-specific and target rna-specific ribozymes

Country Status (9)

Country Link
US (1) US5824519A (fr)
EP (2) EP1561815A3 (fr)
JP (2) JP4033902B2 (fr)
CN (1) CN1207769A (fr)
AT (1) ATE294854T1 (fr)
AU (1) AU728732B2 (fr)
DE (1) DE69634698T2 (fr)
IL (1) IL124383A0 (fr)
WO (1) WO1997017433A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024925A1 (fr) * 1995-11-08 1998-06-11 Medical University Of South Carolina Ribozymes specifiques de tissus, et specifiques d'un arn cible, s'utilisant dans des therapies antimicrobiennes contre des agents pathogenes microbiens
US20030125280A1 (en) * 1996-12-03 2003-07-03 Medical University Of South Carolina Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
AU763325B2 (en) 1998-01-15 2003-07-17 King's College London Ribozymal nucleic acids cleaving CCR5 or CXCR4
EP1088086A4 (fr) * 1998-06-24 2003-01-08 Musc Found For Res Dev Ribozymes specifiques aux tissus et a l'arn cible
AU2004201285B2 (en) * 1998-06-24 2007-07-05 Musc Foundation For Research Development Tissue-specific and target RNA-specific ribozymes
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
MXPA01007366A (es) * 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2365901A1 (fr) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Agents toxiques et ribozymes specifiques de tissu et specifiques de pathogene
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1702983A3 (fr) 2000-04-13 2007-01-10 Medical University of South Carolina Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé
WO2002046449A2 (fr) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection d'acides nucleiques catalytiques cibles sur des agents infectieux
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
JP2005537028A (ja) * 2002-06-26 2005-12-08 ザ　ペン　ステート　リサーチ　ファウンデーション ヒト乳頭腫ウイルス感染症を治療する方法及び材料
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Ｒｎａ干渉組成物および方法
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP2133362B1 (fr) 2003-07-25 2012-04-18 Amgen, Inc Procédés rélatifs aux LDCAM et CRTAM
GB0522578D0 (en) * 2005-11-04 2005-12-14 King S College London Ribozymal nucleic acid
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2307456B1 (fr) 2008-06-27 2014-10-15 Amgen Inc. Inhibition de l ang-2 pour traiter la sclérose en plaques
US9186370B2 (en) 2010-03-19 2015-11-17 University Of South Alabama Methods and compositions for the treatment of cancer
WO2012135696A2 (fr) 2011-04-01 2012-10-04 University Of South Alabama Procédés et compositions pour le diagnostic, la classification et le traitement du cancer
WO2013103401A1 (fr) 2012-01-06 2013-07-11 University Of South Alabama Procédés et compositions pour le traitement du cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2115A1 (fr) * 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
DE3933384A1 (de) * 1989-10-06 1991-04-18 Hoechst Ag Multifunktionelle rna mit selbstprozessierungsaktivitaet, ihre herstellung und ihre verwendung
JP2507895B2 (ja) * 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
JP2580512B2 (ja) * 1990-11-02 1997-02-12 工業技術院長 リボザイムを用いた新規ｒｎａ転写システム
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
WO1992010590A1 (fr) * 1990-12-10 1992-06-25 Gilead Sciences, Inc. Inhibition de transcription par formation de triple helice
GB9216851D0 (en) * 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene

Also Published As

Publication number Publication date
JP2000500967A (ja) 2000-02-02
JP4033902B2 (ja) 2008-01-16
ATE294854T1 (de) 2005-05-15
EP0866852B1 (fr) 2005-05-04
DE69634698T2 (de) 2006-01-19
AU728732B2 (en) 2001-01-18
AU7727296A (en) 1997-05-29
US5824519A (en) 1998-10-20
EP0866852A1 (fr) 1998-09-30
CN1207769A (zh) 1999-02-10
EP1561815A2 (fr) 2005-08-10
EP1561815A3 (fr) 2007-11-07
JP2007084550A (ja) 2007-04-05
WO1997017433A1 (fr) 1997-05-15
DE69634698D1 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
IL124383A0 (en) Tissue-specific and target rna-specific ribozymes
EP1248791A4 (fr) Modulation anti-sens de l'expression de la caspase 3
WO1996019568A3 (fr) Analogues de ribozymes stabilises
EP1131465A4 (fr) Modulation antisens de l'expression de l'interleukine 15
DK1019428T3 (da) Inverterede kimæriske og hybride oligonucleotider
WO1999014346A3 (fr) THERAPIES GENIQUES A BASE D'ARNm SENS
WO2003048324A3 (fr) Modulation antisens de l'expression de la phospholipide scramblase 3
EP1117672A4 (fr) Modulation anti-sens de l'expression de la survivine
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
EP1135402A4 (fr) Modulation antisens de l'expression d'egr-1
EP1189918A4 (fr) Modulation antisens de l'expression d'integrine beta 3
EP1123414A4 (fr) Modulation antisens de l'expression de l'integrine alpha 4
EP1131107A4 (fr) Modulation antisens de l'expression de kappa b kinase alpha inhibitrice
EP1131332A4 (fr) Modulation antisens de l'expression de la kappa b kinase beta inhibitrice
WO2001029175A3 (fr) Modulation antisens de l'expression de fra-1
EP1212456A4 (fr) Modulation antisens de l'expression de shp-2
EP1268507A4 (fr) Modulation antisens de l'expression du facteur de transcription e2f-1
WO2001083513A3 (fr) Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn
EP1144690A4 (fr) Modulation antisens de l'expression d'un inhibiteur cellulaire d'apoptose-2
EP1165145A4 (fr) Regulation antisens d'expression de mdmx
WO2002036810A3 (fr) Modulation antisens de l'expression de la taline
EP1163373A4 (fr) Modulation antisens de l'inhibiteur cellulaire de l'expression de l'apoptose-1
CA2236998A1 (fr) Ribozymes specifiques de tissus ou d'arn cible
EP1235924A4 (fr) Modulation antisens de l'expression de l'activateur du recepteur de facteur kappa b nucleaire (rank)
EP1212455A4 (fr) Modulation antisens de l'expression du facteur 1 de liaison a une repetition telomerique